TrialAnnals of clinical and translational neurology2024

Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study.

Scott D Newsome et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.